BioLingus (Cayman) Limited (SUBL)

BioLingus (Cayman) Limited will go public soon, but the exact IPO date is still unknown.

IPO Price

$20.00

Shares Offered

360,000

Deal Size

$7.20M

SUBL Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year Ending	TTM	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Selling, General & Admin	-	1.1	1.55
Research & Development	-	0.27	0.36
Operating Expenses	-	1.37	1.91
Operating Income	-0.62	-1.37	-1.91
Interest Expense / Income	0.22	0.2	0.11
Other Expense / Income	-0.25	-0.15	0.01
Pretax Income	-0.58	-1.42	-2.03
Net Income	-0.58	-1.42	-2.03
Free Cash Flow	-0.33	-0.55	-1.65
EBITDA	-0.26	-1.06	-1.7
Depreciation & Amortization	0.11	0.16	0.22
EBIT	-0.37	-1.22	-1.92

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).